# RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation

> **NCT03948529** · PHASE2 · TERMINATED · sponsor: **University Hospital, Lille** · enrollment: 9 (actual)

## Conditions studied

- Leukemia
- Graft Failure

## Interventions

- **DRUG:** eltrombopag

## Key facts

- **NCT ID:** NCT03948529
- **Lead sponsor:** University Hospital, Lille
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-05
- **Primary completion:** 2023-02-24
- **Final completion:** 2023-08-21
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** inclusions difficulties.
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03948529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03948529, "RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03948529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*